# Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults

> **NCT02840474** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 16 (actual)

## Conditions studied

- HIV-1

## Interventions

- **BIOLOGICAL:** VRC-HIVMAB080-00-AB
- **BIOLOGICAL:** VRC-HIVMAB075-00-AB

## Key facts

- **NCT ID:** NCT02840474
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-24
- **Primary completion:** 2020-01-15
- **Final completion:** 2020-01-15
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02840474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02840474, "Phase 1, Open-label, Single Dose Study to Examine Safety, Tolerability, Pharmacokinetics and Virologic Impact of VRC01LS or VRC07-523LS in HIV-infected Viremic Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02840474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*